A Long-term Outcomes Study to Assess Statin Residual Risk Reduction with EpaNova High Cardiovascular Risk Patients witgh Hypertriglyceridemia (STRENGTH)

StatusActive
Effective start/end date8/06/1530/06/24

Funding

  • Astra Zeneca: $137,273.90

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research